



VEOZA (fezolinetant) is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.<sup>1</sup>

VMS are also known as hot flushes\* and night sweats.<sup>2</sup>

The Prescribing Information for VEOZA (fezolinetant) can be accessed by a scannable and clickable QR Code on the back page.



## FIGHT *the* FIRE WITH NON-HORMONAL VEOZA

VEOZA is the first-in-class selective neurokinin 3 (NK3) receptor antagonist to be licensed. It blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron, which is postulated to restore the balance in KNDy neuronal activity in the thermoregulatory centre of the hypothalamus.<sup>1,3,4</sup>

KNDy: kisspeptin/neurokinin B/dynorphin, NK3: neurokinin 3, NKB: neurokinin B, VMS: vasomotor symptoms.

\*Hot flushes are also known as hot flashes.<sup>3</sup>

**NON-HORMONAL**


**Adverse events should be reported.  
Reporting forms and information can be found at  
[www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for  
MHRA Yellow Card in the Google Play or Apple App Store.  
Adverse events should also be reported to  
Astellas Pharma Ltd. on 0800 783 5018.**

# HOW VEOZA DISRUPTS HOT FLUSHES

## HOW VMS START

### Homeostasis

KNDy neurons in the hypothalamus are inhibited by oestrogen and stimulated by the neuropeptide, NKB. This balance contributes to **body temperature regulation**.<sup>3</sup>



### Menopause


Oestrogen decline during menopause disrupts this balance with NKB. **Unopposed, NKB signalling** causes heightened KNDy neuronal activity.<sup>3</sup> This **triggers heat dissipation** mechanisms, including vasodilation and sweating—VMS.<sup>3</sup>



## VEOZA

### Blocking NKB to reduce the heat

**VEOZA selectively** binds to the NK3 receptor to **block NKB**.<sup>1</sup> This action moderates NKB signalling and KNDy neuron activity, helping to restore thermoregulatory balance and better control VMS.<sup>1,3</sup>



Put VEOZA to work for your appropriate menopause patients suffering from VMS

KNDy: kisspeptin/neurokinin B/dynorphin, NK3: neurokinin 3, NKB: neurokinin B, ORα: oestrogen receptor alpha, VMS: vasomotor symptoms.



# REDEFINE HOW YOU TARGET VMS

A non-hormonal option for eligible patients with moderate to severe VMS associated with menopause.<sup>1</sup>

**VEOZA directly and selectively targets a source of VMS - the NK3 receptor on KNDy neurons in the hypothalamus.<sup>1</sup>**



*Block*  
**THE BINDING  
OF NKB<sup>1</sup>**

*Reduce*  
**KNDy NEURONAL  
ACTIVITY<sup>1,3</sup>**

*Balance*  
**TEMPERATURE  
CONTROL  
CENTRE ACTIVITY<sup>1,3</sup>**

**Put VEOZA to work for your appropriate  
menopause patients suffering from VMS**

KNDy: kisspeptin/neurokinin B/dynorphin, NK3: neurokinin 3, NKB: neurokinin B, VMS: vasomotor symptoms.

  
**VEOZA™**  
fezolinetant

**For further information about  
VEOZA please visit:  
[www.veoza.co.uk](http://www.veoza.co.uk)**

**Please scan or click on the following Quick Response (QR) code to access  
the Prescribing Information for VEOZA.**

---

**References:** **1.** VEOZA Summary of Product Characteristics. **2.** Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, *et al.* eds. Menopause Practice: A Clinician's Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43–55. **3.** Depypere H, Lademacher C, Siddiqui E, *et al.* Fezolinetant in the treatment of vasomotor symptoms associated with menopause. *Expert Opin Investig Drugs* 2021;30(7):681–94. **4.** Jayasena CN, Comninou AN, Stefanopoulou E, *et al.* Neurokinin B administration induces hot flushes in women. *Sci Rep* (Epub) 02-16-2015.

---